热门资讯> 正文

Mereo BioPharma集团GAAP每股收益为-0.02美元

2024-08-13 21:03

Mereo BioPharma Group press release (NASDAQ:MREO): Q2 GAAP EPS of -$0.02.
As of June 30, 2024, the Company had cash and cash equivalents of $87.4 million, compared to $57.4 million as of December 31, 2023.

More on Mereo BioPharma Group

Mereo BioPharma: Positioned For Potential Breakthroughs
Baird starts Mereo at outperform, sees alvelestat as underappreciated
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
Seeking Alpha’s Quant Rating on Mereo BioPharma Group
Historical earnings data for Mereo BioPharma Group

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。